このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Phase 1b Study of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Non-Gain-of-Function Variants (4sight)

2026年11月10日 更新者:GRIN Therapeutics, Inc.

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 1b Study With an Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function

This is a multinational, multicenter, randomized, double-blinded, placebo-controlled, Phase 1b study with an open-label extension (OLE) to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related neurodevelopmental disorder (GRIN-NDD) in children with a genetic variant characterized as non-gain-of-function.

This study will consist of Part A (blinded, placebo-controlled) and Part B (blinded transition followed by an OLE).

Participants will be randomized in a 2:1 ratio to receive active drug (radiprodil) or matching placebo (Part A) and stratified by functional characterization (either indeterminant, LoF, or no effect). Following completion of Part A, all eligible participants (including those previously on placebo) may continue into the open-label extension period (Part B) to receive radiprodil.

The placebo-controlled portion is expected to be approximately 17 weeks for participants in Part A and at least 12 months for participants in Part B.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

Participants are assigned in a 2:1 ratio to receive either radiprodil or placebo during Part A with the opportunity to receive radiprodil in the Part B OLE.

This study is divided into the following parts:

Part A: Randomized, double-blind, placebo-controlled

  • Screening/Observation Period: To assess eligibility (approximately 5 weeks)
  • Titration Period (approximately 4 weeks): Titration of radiprodil or placebo to target dose
  • Maintenance Period (Part A): Target dose of radiprodil or placebo maintained for 8 weeks
  • Tapering and Follow-up Period: Gradual decrease and Follow-up Period for participants not entering Part B

Part B: Open-label safety follow-up period

  • Blinded Titration Period (approximately 4 weeks): Titration of radiprodil to target dose
  • Open-Label Treatment Period: Participants will continue to receive radiprodil until such time as either the participant withdraws/is withdrawn from the study, Sponsor terminates the study, or market access is available
  • Tapering and Follow-up Period: Gradual decrease and follow-up observation period for participants upon leaving the study

研究の種類

介入

入学 (推定)

27

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1ヶ月~18年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

Part A, Participant:

  • Diagnosed with GRIN-NDD with GRIN1, GRIN2A, GRIN2B, or GRIN2D gene variants known to result in a functional characterization that is loss of function, indeterminant, or no effect
  • Inadequately controlled seizures of any type with clinically significant EEG abnormalities per EEG collected within 12 months of Screening or during the Screening Period
  • Receiving at least 1 standard antiseizure medication (ASM)
  • On a stable dose of standard ASM for at least 4 weeks prior to screening and should remain on stable dose throughout study participation
  • Nonpharmacological treatments such as ketogenic diet should remain stable throughout study participation
  • Participant's caregivers are willing and able to complete entries in the eDiary on a daily basis and have demonstrated compliance

Part B, Participant:

- Has completed Part A and is eligible to continue study participation according to the judgment of the Investigator and Sponsor.

Exclusion Criteria:

PART A, Participant:

  • Has clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation or study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.
  • Is receiving >4 standard ASMs at screening
  • Has a body weight of less than 5 kg at screening
  • Participant or caregiver is unwilling or unable to comply with all study procedures for the duration of the study.
  • Has clinically significant laboratory or ECG abnormalities according to the judgment of the Investigator or Sponsor
  • Has severe hepatic dysfunction (Child-Pugh grade C)
  • Has a history of brain surgery within 6 months of randomization for epilepsy or any other reason
  • Is receiving treatment with prohibited concomitant drugs such as agonists or antagonists of the glutamate receptor, including but not limited to felbamate, memantine, and perampanel
  • Is receiving treatment with a strong CYP3A4 inhibitor (eg, itraconazole or some antimicrobials that are strong inhibitors) that has not been discontinued at least 5 half-lives prior to the planned first dose of radiprodil
  • Has received any prior gene therapy
  • Is on treatment with hormonal therapy such as adrenocorticotrophic hormone or prednisolone

Part B Participant:

  • Has clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation of study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.
  • Participant or caregiver is unwilling or unable to comply with all study procedures for the duration of the study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Radiprodil oral suspension

Liquid suspension of radiprodil, at varying concentrations depending on participant's weight.

The following dose-escalation regimen (twice daily [BID]) will be used:

Titration Period Visit 1 (Visit T1): Dose 1, Visit T2: Dose 2, Visit T3: Dose 3, Visit T4: Maintenance Dose.

Radiprodil oral suspension

プラセボコンパレーター:Placebo-to-match radiprodil oral suspension

Liquid suspension of placebo matching radiprodil oral suspension and dose-escalation regimen.

Placebo-to-match radiprodil oral suspension

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Adverse Events (AEs)
時間枠:From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).

Number and percentage of participants experiencing adverse events (AEs). AEs will be assessed by frequency, type, severity, and duration. Treatment-emergent AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by System Organ Class and Preferred Term.

From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
Serious Adverse Events (SAEs)
時間枠:From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).

Number and percentage of participants experiencing serious adverse events (SAEs). SAEs will be assessed by frequency, type, severity, and duration, including treatment-emergent SAEs and SAEs considered related to investigational product.

From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
Adverse Drug Reactions (ADRs)
時間枠:From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).

Number and percentage of participants experiencing adverse drug reactions (ADRs). ADRs will be assessed by frequency, type, severity, and duration and summarized by functional characterization, study part, and overall.

From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
Change From Baseline in Blood Pressure
時間枠:From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in blood pressure (mmHg), assessed at scheduled study visits. Observed values and changes from Baseline will be summarized using descriptive statistics.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in Pulse Rate
時間枠:From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in pulse rate (beats per minute), assessed at scheduled study visits. Observed values and changes from Baseline will be summarized using descriptive statistics.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Physical Examination Findings
時間枠:From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants with abnormal physical or neurological examination findings. Findings will be listed, and findings indicative of adverse events will be included in adverse event summaries.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG Pulse Rate
時間枠:From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in pulse rate measured by 12-lead electrocardiogram (ECG), expressed in beats per minute (bpm).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG RR Interval
時間枠:From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in the RR interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG PR Interval
時間枠:From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in the PR interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG QRS Duration
時間枠:From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in QRS duration measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG QT Interval
時間枠:From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in the QT interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG QTcF Interval
時間枠:From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in the QT interval corrected using Fridericia's formula (QTcF), measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Clinically Significant Changes in Clinical Laboratory Parameters
時間枠:From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants with clinically significant abnormalities or changes in clinical laboratory parameters, including hematology, serum chemistry, and coagulation assessments. Laboratory values and changes from Baseline will be summarized, and clinically significant abnormal values listed separately.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Emergence of New Seizure Types
時間枠:From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants experiencing new seizure types compared with Baseline. Emergence of new seizure types will be tabulated overall and by seizure type at scheduled assessments.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Occurrence of Suicidal Ideation
時間枠:From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants experiencing suicidal ideation at any post-Baseline assessment, based on the Columbia-Suicide Severity Rating Scale (C-SSRS) or investigator assessment, as appropriate for the participant.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Occurrence of Suicidal Behavior
時間枠:From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants experiencing suicidal behavior at any post-Baseline assessment, based on the Columbia-Suicide Severity Rating Scale (C-SSRS) or investigator assessment, as appropriate for the participant.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

二次結果の測定

結果測定
メジャーの説明
時間枠
Plasma Concentration of Radiprodil
時間枠:From first dose through study completion, including Part A (12 weeks of treatment) and Part B (anticipated at least 12 months).

Plasma concentrations of radiprodil will be measured at predefined pharmacokinetic (PK) sampling timepoints.

From first dose through study completion, including Part A (12 weeks of treatment) and Part B (anticipated at least 12 months).
Change From Baseline in SERIAS Green Light Days
時間枠:Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).

Change from Baseline to the end of the Part A Maintenance Period in the number of green light days, assessed using the Seizure-Related Impact Assessment Scale (SERIAS) and captured in the daily electronic diary (eDiary).

Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).
Change From Baseline in SERIAS Yellow Light Days
時間枠:Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).

Change from Baseline to the end of the Part A Maintenance Period in the number of yellow light days, assessed using SERIAS and captured in the daily eDiary.

Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).
Change From Baseline in SERIAS Red Light Days
時間枠:Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).

Change from Baseline to the end of the Part A Maintenance Period in the number of red light days, assessed using SERIAS and captured in the daily eDiary.

Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).
Change From Baseline in Total Countable Seizure Frequency per 28 Days
時間枠:Baseline (last 4 weeks before randomization) through Part A Maintenance Period (8 weeks).

Change from Baseline in total countable seizure frequency normalized to 28 days during the Part A Maintenance Period (Weeks 1 through 8), as recorded in the daily seizure eDiary.

Baseline (last 4 weeks before randomization) through Part A Maintenance Period (8 weeks).
Change From Baseline in EEG Spike Rate
時間枠:Baseline through Part A Maintenance Period (Weeks 1 through 8).

Change from Baseline in electroencephalogram (EEG) spike rate, expressed as spikes per hour, during the Part A Maintenance Period.

Baseline through Part A Maintenance Period (Weeks 1 through 8).
Change From Baseline in EEG Background Activity
時間枠:Baseline through Part A Maintenance Period (Weeks 1 through 8).

Change from Baseline in electroencephalogram (EEG) background activity during the Part A Maintenance Period.

Baseline through Part A Maintenance Period (Weeks 1 through 8).
Percentage of Participants With at Least 50% Reduction in Total Countable Seizure Frequency
時間枠:Baseline (last 4 weeks before randomization) to the end of Part A Maintenance Period (8 weeks).

Percentage of participants achieving at least a 50% reduction in total countable seizure frequency per 28 days from Baseline (the last 4 weeks before randomization) to the entire Part A Maintenance Period.

Baseline (last 4 weeks before randomization) to the end of Part A Maintenance Period (8 weeks).
Percentage of Participants With at Least 50% Reduction in Total Seizure Frequency
時間枠:Baseline through Part A and Part B, as assessed.

Percentage of participants achieving at least a 50% reduction in total seizure frequency compared with Baseline.

Baseline through Part A and Part B, as assessed.
Percent Change From Baseline in Total Countable Seizure Frequency
時間枠:Baseline through Part A and Part B, as assessed.

Percent change from Baseline in total countable seizure frequency normalized to 28 days. Percent change is calculated relative to the Baseline seizure frequency.

Baseline through Part A and Part B, as assessed.
Proportion of Seizure-Free Days
時間枠:Baseline through Part A and Part B, as assessed.

Proportion of days without seizures during the assessment period, based on seizure data recorded in the daily eDiary.

Baseline through Part A and Part B, as assessed.
Longest Interval of Seizure Freedom
時間枠:Baseline through Part A and Part B, as assessed.

Longest consecutive interval without seizures during the assessment period, based on seizure data recorded in the daily eDiary.

Baseline through Part A and Part B, as assessed.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Michelle Pritikin、GRIN Therapeutics, Inc.
  • スタディディレクター:Aneeta Saxena、GRIN Therapeutics, Inc.

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月1日

一次修了 (推定)

2027年10月1日

研究の完了 (推定)

2027年12月1日

試験登録日

最初に提出

2026年11月5日

QC基準を満たした最初の提出物

2026年11月10日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • RAD-GRIN-102

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。